A multicomponent treatment program for kidney patients in Stages 3, 4, 4a, 4b, and 5, who are not on dialysis, comprising administering daily a: low nitrogen diet; low nitrogen protein food comprising magnesium and/or calcium salts of alpha keto acids; and time released vitamin. The vitamin comprises the active ingredients of: Zinc; Selenium; Vitamins B1, B2, B6, B12, B5, E, and K2; Niacin; superoxide dismutase; catalase; glutathione and Folate; and excludes calcium, magnesium, phosphorus, sodium, manganese, fluoride, Vitamin D and K1. The low nitrogen food contains daily up to 300 mg of nitrogen; and at least five alpha keto analogues of magnesium and/or calcium salts of: leucine, isoleucine, methionine (MEMS-II), phenylalanine (PAMS-I), and valine. Methods of making and the chemical structures MEMS-II and the PAMS-I are disclosed. The treatment results in an increase of Glomerular Filtration Rate (GFR), a decrease in blood urea levels, and a decrease in creatinine levels.

Described herein are methods for the manufacture of compositions useful for the treatment of meibomian gland dysfunction. Said methods utilize rheological properties of petrolatum induced by a high shear mixing feature of the method. The products of the methods of manufacture described herein are stable anhydrous composition of selenium disulfide which are substantially free of selenium disulfide agglomerates and degradation products.

Described herein are methods for the manufacture of compositions useful for the treatment of meibomian gland dysfunction. Said methods utilize rheological properties of petrolatum induced by a high shear mixing feature of the method. The products of the methods of manufacture described herein are stable anhydrous composition of selenium disulfide which are substantially free of selenium disulfide agglomerates and degradation products.

An antimicrobial agent comprising a selenium nanoparticle (SeNP) core and one or more superficially located antimicrobial peptide/s (AMP). The or each AMP may comprise an excess of positively charged amino acids compared to negatively charged amino acids and the AMP may comprise peptides from classes selected from polylysine, such as ε-poly-L-lysine (ε-PL), polyarginine, aurein, ovispirin, melittin, magainin, cecropin, andropin, moricin, ceratotoxin, melittin, magainin, dermaseptin, bombinin, brevinin, esculentins, buforin, cathelicidin, abaecin, apidaecin, prophenin and indolicidin. Products comprising such agents, methods of producing the agents and methods of killing or retarding growth of microorganisms exposed to the agents are also disclosed.

An antimicrobial agent comprising a selenium nanoparticle (SeNP) core and one or more superficially located antimicrobial peptide/s (AMP). The or each AMP may comprise an excess of positively charged amino acids compared to negatively charged amino acids and the AMP may comprise peptides from classes selected from polylysine, such as ε-poly-L-lysine (ε-PL), polyarginine, aurein, ovispirin, melittin, magainin, cecropin, andropin, moricin, ceratotoxin, melittin, magainin, dermaseptin, bombinin, brevinin, esculentins, buforin, cathelicidin, abaecin, apidaecin, prophenin and indolicidin. Products comprising such agents, methods of producing the agents and methods of killing or retarding growth of microorganisms exposed to the agents are also disclosed.

An antimicrobial agent comprising a selenium nanoparticle (SeNP) core and one or more superficially located antimicrobial peptide/s (AMP). The or each AMP may comprise an excess of positively charged amino acids compared to negatively charged amino acids and the AMP may comprise peptides from classes selected from polylysine, such as ε-poly-L-lysine (ε-PL), polyarginine, aurein, ovispirin, melittin, magainin, cecropin, andropin, moricin, ceratotoxin, melittin, magainin, dermaseptin, bombinin, brevinin, esculentins, buforin, cathelicidin, abaecin, apidaecin, prophenin and indolicidin. Products comprising such agents, methods of producing the agents and methods of killing or retarding growth of microorganisms exposed to the agents are also disclosed.

There are provided various compositions comprising monoglyceride(s) and cannabinoid(s). These compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject.

There are provided various compositions comprising monoglyceride(s) and cannabinoid(s). These compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject.

The invention relates to a medical product for preventing or correcting selenium deficiency in a patient comprising a solution provided in a flexible container characterized in that the solution comprises at least one of a selenate salt and/or a seleno-amino acid, such as selenomethionine or selenocysteine.

The invention relates to a medical product for preventing or correcting selenium deficiency in a patient comprising a solution provided in a flexible container characterized in that the solution comprises at least one of a selenate salt and/or a seleno-amino acid, such as selenomethionine or selenocysteine.